Safety and tolerability of eprosartan

The safety and tolerability of eprosartan were extensively assessed in 17 p hase IIb-III studies that included 2709 patients with hypertension. The fre quency of adverse events observed with eprosartan was similar to that seen with placebo. Neither the number nor the severity of these effects increase d with prolonged therapy, and their frequency was not affected by increased eprosartan dosage or dosing frequency. The drug is equally well tolerated by women and men, by younger (< 65 yrs) and older (greater than or equal to 65 yrs) individuals, and by persons of all races. There are no known drug interactions, and eprosartan is well tolerated when given in combination wi th other frequently prescribed antihypertensive agents, without an increase in adverse events beyond those expected of baseline antihypertensive thera py.